Catalog No.
Product Name
Application
Product Information
Citations
-
Parasite Inhibitor
Tectol is a farnesyltransferase inhibitor, effectively targeting the enzyme in both human and Trypanosoma brucei systems. With IC50 values of 2.09 μM and 1.73 μM respectively, Tectol demonstrates potent antitumor activity against human leukemia cell lines HL60 and CEM. In addition, it exhibits significant inhibitory effects on the drug-resistant strain of Plasmodium falciparum (FcB1), with an IC50 of 3.44 μM, making it a valuable tool for researching parasitic and cancer biology. -
PfGSK3/PfPK6 Inhibitor
PfGSK3/PfPK6-IN-1 is a selective inhibitor targeting PfGSK3 and PfPK6, with IC50 values of 97 nM and 8 nM, respectively. This compound effectively inhibits the proliferation of blood-stage Plasmodium falciparum 3D7 parasites, making it a valuable tool for malaria research. Additionally, PfGSK3/PfPK6-IN-1 exhibits low cytotoxicity in hepatocyte cultures at concentrations up to 200 nM, with a significant reduction in cell viability observed at 2 μM. Its dual action enhances its potential in studying malaria-related mechanisms and potential therapeutic strategies. -
Antiparasite Agent
13,21-Dihydroeurycomanone is a natural compound derived from the root of Eurycoma longifolia, known for its antiparasitic properties. It displays significant activity against Plasmodium falciparum and Toxoplasma gondii, making it a valuable candidate for research on antiparasitic therapies. Its role in inhibiting these pathogens provides insights for the development of new treatments for malaria and toxoplasmosis. -
Parasite Inhibitor
Melarsonyl, also known as Melarsonic acid, is an anthelmintic agent that targets and inhibits parasitic organisms. It exhibits potent activity against a variety of parasites, making it valuable in research aimed at understanding and combating parasitic infections. This compound is utilized in the study of helminthic diseases and other related areas in parasitology. -
Parasite Inhibitor
Piperazine adipate is an effective anthelmintic agent that targets parasitic worms in mammals. Its broad-spectrum activity makes it suitable for treating various helminth infections, thereby providing significant therapeutic benefits in veterinary and clinical settings. This compound is utilized in research to explore mechanisms of helminth resistance and to develop novel treatment protocols against parasitic infections. -
Antileishmanial Agent
Niazinin is a thiocarbamate glycoside that serves as an antileishmanial agent with an IC50 value of 5.25 μM. It demonstrates potent leishmanicidal activity and exhibits binding affinity to the target protein 3CL protease. Additionally, Niazinin possesses anti-inflammatory and antipyretic properties, making it a valuable compound for research in tropical diseases and inflammatory conditions. -
Antileishmanial Agent
Phylloflavan is an antileishmanial agent that targets intracellular pathways, exhibiting an EC50 of 3.2 nM in RAW 264.7 cells. Additionally, Phylloflavan demonstrates the ability to inhibit the cytopathic effect of encephalomyocarditis virus in L929 fibroblast cells at a concentration of 38 U/mL. This compound is relevant for research applications focused on leishmaniasis and viral infections. -
Parasite
Triazophos is a potent non-systemic insecticide and acaricide that functions as an acetylcholinesterase (AChE) inhibitor. By covalently and irreversibly binding to the acetylcholine binding site, Triazophos effectively disrupts the hydrolysis of acetylcholine, resulting in increased neuroexcitability. This compound demonstrates efficacy against a broad spectrum of soil insects and mites, including aphids, thrips, and spider mites, making it valuable for crop protection in various agricultural settings, such as ornamentals, cotton, rice, maize, soybeans, oil palms, olives, and coffee. -
Parasite Inhibitor
Phosalone is an organophosphate insecticide that primarily targets acetylcholinesterase, leading to the inhibition of neurotransmission in parasites. Its potent biological activity makes it effective in controlling a wide range of insect pests. Phosalone is utilized in entomological research and in studies focusing on pest management strategies and the biochemical pathways of insecticide resistance. -
Parasite Inhibitor
trans-Permethrin is a synthetic pyrethroid that primarily targets the nervous system of insects, functioning as a potent insecticide and neurotoxin. Its primary biological activity involves disrupting sodium channel function, leading to paralysis and death in targeted pest populations. This compound is widely used in research applications aimed at understanding insecticide resistance mechanisms and developing novel pest control strategies. -
Parasite
22,23-Dihydroavermectin B1a aglycon is a hydrolysis-derived degradation product of ivermectin that targets parasitic nematodes. This compound effectively inhibits the larval development of nematodes without inducing paralysis, making it useful for studying nematode biology and potential therapeutic applications. Its specific mechanism of action contributes to research in parasitology and the development of antiparasitic agents. -
Antiparasite Agent
Ile-AMS is an antiparasitic agent that exerts its activity against Plasmodium falciparum, with an ABS IC50 value of 1.19 nM. This compound is essential for studying malaria pathogenesis and can aid in the development of effective therapeutic strategies. Its potent inhibition of P. falciparum makes it a valuable tool in malaria research and drug discovery efforts. -
Parasite Inhibitor
Bitoscanate, also known as p-Phenylene diisothiocyanate, primarily acts as a parasite inhibitor. It demonstrates significant activity against hookworms, making it valuable in the therapeutic management of parasitic infections. Its biological properties facilitate research applications focused on developing effective treatments for helminthic diseases. -
Aniti-parasite Agent
epi-Ivermectin B1a is a significant derivative of Ivermectin, functioning as an anti-parasitic agent. This compound serves as a valuable tool for researching internal and external parasites, particularly in cattle. Its role in understanding the efficacy and safety of ivermectin-based formulations enhances its relevance in parasitology studies. -
Parasite Inhibitor
CWHM-1552 is a potent inhibitor of Plasmodium falciparum, demonstrating IC50 values of 51 nM and 53 nM against the 3D7 and Dd2 strains, respectively. This compound exhibits significant efficacy in oral administration and is designed for research applications focused on malaria treatment and parasite biology. CWHM-1552 serves as a valuable tool for studying antimalarial mechanisms and developing novel therapeutic strategies. -
Antileishmanial Agent
Trypaflavin is an acridine derivative recognized for its antileishmanial activity. It exerts its effects by targeting germ cells and inducing chromosomal aberrations in unfertilized oocytes, resulting in increased rates of genetic instability. Notably, Trypaflavin demonstrates significant toxicity toward Leishmania, leading to immediate lysis of leptomonads. This compound serves as a valuable tool in the study of leishmaniasis and related cellular processes. -
Parasite Inhibitor
Anticancer agent 140 is a compound designed as a parasite inhibitor, exhibiting significant potential for anticancer and antiparasitic activities. This reagent targets specific cellular pathways, making it valuable for research in cancer biology and parasitology. Its effectiveness in inhibiting parasite proliferation underscores its relevance in drug discovery and development for related diseases. -
Parasite Inhibitor
Mirincamycin hydrochloride is a potent inhibitor of malaria, specifically targeting the early liver stages of Plasmodium. This compound demonstrates protective effects, effectively preventing the progression of the parasite during its initial infection phase. However, it is important to note that Mirincamycin does not eliminate dormant liver stages, as observed in studies utilizing a rhesus monkey model. This characteristic limits its applicability in certain therapeutic scenarios against malaria. -
Parasite Inhibitor
Allylpyrocatechol is a parasite inhibitor known for its antimalarial activity. This compound has been validated for its efficacy both in vitro and in vivo, demonstrating significant potential in combating malaria. Additionally, structure-activity relationship analyses of its analogs have been conducted, providing insights into the mechanisms underlying its biological effects. Its application in research can contribute to the development of novel antimalarial therapies. -
Parasite Inhibitor
BiPNQ is a potent inhibitor of Trypanosoma cruzi, the protozoan responsible for Chagas disease. This compound effectively disrupts the biological processes of the parasite, making it a valuable tool for research focused on the treatment of Chagas disease and the development of antiparasitic therapies. Its inhibitory activity may help elucidate the mechanisms of infection and potential therapeutic targets. -
Antileishmanial Agent
Antileishmanial agent-18 is an effective inhibitor of Leishmania donovani promastigote growth, targeting the parasite responsible for visceral leishmaniasis. This compound demonstrates notable antileishmanial activity while exhibiting a low cytotoxicity profile in host cells, making it a valuable tool for research into leishmaniasis treatment options. Its application is relevant in studies aimed at understanding parasite biology and developing new therapeutic strategies against leishmaniasis. -
Parasite Inhibitor
Ludaconitine, derived from Aconitum spicatum (Bruhl) Stapf, functions as a potent inhibitor of parasites. It demonstrates significant antileishmanial activity, exhibiting an IC50 of 36.10 μg/mL. This compound is valuable for research applications focused on leishmaniasis and the exploration of novel antiparasitic agents. -
Anti-parasite Agent
PAM 1392 is an anti-parasitic agent with demonstrated efficacy against Plasmodium berghei in murine models, as well as P. cynomolgi and P. knowlesi in non-human primates. Additionally, it exhibits significant anti-Trypanosoma cruzi activity in murine tissue cultures and acts against hemolytic streptococci in vitro. The dual antimalarial and antitrypanosomal properties of PAM 1392 make it a valuable compound for research focused on drug-resistant malaria and related parasitic diseases. -
Antileishmanial Agent
Antileishmanial agent-5 is a ribonucleoside analogue that exhibits potent activity against Leishmania infantum and Trypanosoma cruzi. It demonstrates effective antileishmanial properties, with EC50 values of 0.68 μM and 0.83 μM, respectively. This compound serves as a valuable tool for research applications focused on the treatment of leishmaniasis and Chagas disease. -
Parasite Inhibitor
Ep vinyl quinidine, an epi-vinyl stereoisomer of Quinidine, serves as a targeted inhibitor of parasitic activity. This compound exhibits significant potential in malaria research, leveraging its capabilities as a selective cytochrome P450db inhibitor. Additionally, it functions as a potassium channel blocker with an IC50 of 19.9 μM, positioning it as a valuable tool for investigating anti-parasitic mechanisms and therapeutic interventions. -
Antileishmanial Agent
DNDI-VL-2098 is an orally active antileishmanial agent targeting Leishmania parasites. It demonstrates high permeability and in vitro metabolic stability while selectively inhibiting CYP2C19, with an IC50 of 0.47 μM, without affecting other major CYP enzymes at concentrations up to 12.5 μM. This compound exhibits favorable pharmacokinetic properties across various animal models, including mice, hamsters, rats, and dogs, with moderate to high plasma protein binding. DNDI-VL-2098 is a valuable reagent for the study of visceral leishmaniasis. -
Parasite Inhibitor
Antileishmanial agent-1 specifically targets Leishmania parasites, demonstrating potent inhibitory activity against L. amazonensis promastigotes with an IC50 of 15.52 μM and intracellular amastigotes with an IC50 of 4.10 μM. This compound is valuable for research focused on leishmaniasis treatment, facilitating studies on parasite bioenergetics and drug resistance mechanisms. Its ability to effectively inhibit parasite growth makes it a significant tool in the development of antileishmanial therapies. -
Antileishmanial Agent
Antileishmanial agent-15 primarily targets Leishmania spp. and exhibits significant antileishmanial activity. This compound demonstrates cytotoxic effects against L. major promastigotes and amastigotes, with IC50 values of 0.78 μM and 0.99 μM, respectively. It serves as a valuable tool for research aimed at developing treatments for leishmaniasis. -
Parasite Inhibitor
Melilotigenin C is a natural product derived from the genus Erythrina, primarily acting as a parasite inhibitor. It exhibits significant antiplasmodial activity, making it a candidate for studies focused on malaria treatment. Additionally, Melilotigenin C demonstrates antimycobacterial properties and presents potential for cytotoxicity research, contributing to the exploration of new therapeutic agents against infectious diseases. -
Parasite Ubiquinol Oxidation Site Inhibitor
ELQ-121 is a potent inhibitor targeting the ubiquinol oxidation site in parasites. It exhibits remarkable antimalarial activity, with an IC50 of 0.05 nM against both chloroquine-sensitive and multidrug-resistant strains of P. falciparum in vitro. Additionally, ELQ-121 demonstrates high efficacy against T. gondii and N. caninum, with IC50 values below 1 nM, and suppresses B. besnoiti tachyzoite proliferation with an IC50 of 0.49 nM, accompanied by mitochondrial disruption. Furthermore, the compound can be formulated as a polyethylene glycol carbonate ester prodrug, showing in vivo efficacy against P. yoelii in mice, making it a valuable tool for antimalarial research. -
Parasite Inhibitor
BRD5018 is a selective antimalarial agent that targets Plasmodium parasites. This compound functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its ability to facilitate this reaction expands its utility in chemical biology applications, particularly in the development of novel therapeutic strategies against malaria. -
Parasite
trans-Methylisoeugenol acts as an insect chemosterilant, primarily targeting parasites. Isolated from Acorus calamus L., this compound demonstrates significant biological activity by inhibiting reproductive capabilities in various insect species. It has applications in pest control research and studies focused on parasitic insect management. -
Antileishmanial Agent
Antileishmanial agent-11 is a potent antileishmanial compound that primarily targets Leishmania species. It exhibits significant antiprotozoal activity, with IC50 values of 28.3 μM against Leishmania braziliensis, 24.8 μM against Leishmania infantum, and 13.0 μM against Trypanosoma cruzi. This compound is valuable for research focused on leishmaniasis and Chagas disease, providing a useful tool for understanding protozoan infections and exploring potential therapeutic strategies. -
Antileishmanial Agent
Antileishmanial agent-9 is a potent and selective compound targeting Leishmania donovani, exhibiting an IC50 value of 4.01 μM. This agent demonstrates significant antileishmanial activity while maintaining relatively low cytotoxicity in L-6 cells, with an IC50 of 40.1 μM. It serves as a valuable tool for research applications focusing on leishmaniasis treatment and drug development. -
Parasite
Clioxanide is an investigational agent targeting the parasite Fasciola hepatica, known for causing liver fluke infections. Research indicates that Clioxanide demonstrates limited efficacy against both 4-week-old and 19-week-old liver flukes at doses of 135 mg/kg and 200 mg/kg. Importantly, no significant toxicological effects were noted in laboratory mice, suggesting a favorable safety profile. This compound may serve as a valuable addition to studies aimed at developing treatments for liver fluke infections in livestock species, although its effectiveness warrants further investigation. -
Parasite Modulator
TCMDC-136230 is a novel modulator of calcium dynamics in malaria parasites. It effectively disrupts calcium regulation while showing minimal inhibition of heme crystallization. This compound is valuable for research focused on developing new antiparasitic therapies and understanding the molecular mechanisms underlying malaria pathogenesis. -
Parasite Inhibitor
Antimalarial agent 2 is a novel compound that targets Plasmodium parasites, displaying a rapid in vitro killing profile. This reagent demonstrates potent antiparasitic activity, making it a valuable tool for research into malaria treatment and the development of effective antimalarial therapies. Its oral efficacy indicates potential for further exploration in therapeutic applications against malaria. -
Parasite Modulator
TCMDC-125457 is a potent parasite modulator that induces calcium redistribution while minimally inhibiting heme crystallization. This compound has shown high efficacy in a single-dose combination with artesunate, particularly against tightly synchronized artemisinin-resistant ring-stage parasites. Its unique mechanism and activity position TCMDC-125457 as a valuable tool for research into antimalarial therapies and the understanding of drug resistance in parasitic infections. -
Anti-parasite Agent
Lychnopholide is a sesquiterpene lactone targeting Trypanosoma cruzi, demonstrating significant anti-trypanosomal activity. This compound has been shown to effectively reduce toxicity to mammalian cells when encapsulated in nanocapsules, enhancing its therapeutic potential. Lychnopholide is utilized in research focused on Chagas disease, providing valuable insights in mouse model studies for potential treatment strategies. -
Antileishmanial Agent
Antileishmanial agent-14 is a sulfuretin analog targeting Leishmania donovani, demonstrating significant antileishmanial activity. With an IC50 of 4.1 μM against promastigotes and an IC50 of 11.1 μM against amastigotes, this compound shows promise for inhibiting the infection cycle of the parasite. Its effectiveness makes it a valuable tool for research into leishmaniasis treatment and further investigation of related therapeutic strategies. -
Parasite Inhibitor
Carbarsone, or p-ureidobenzenearsonic acid, primarily functions as a parasite inhibitor with notable efficacy as an amebicide. Historically utilized in human and veterinary medicine, it has been incorporated into poultry and swine feed to mitigate conditions such as blackhead in turkeys, often in conjunction with antibiotics. Its relatively low acute toxicity has prompted research into its safety as a food additive, with studies indicating minimal carcinogenic risk under chronic ingestion, similar to other arsanilic acid derivatives. Carbarsone is metabolized to arsanilic acid, which has been investigated in high-dose studies in canine models. -
Antileishmanial Agent
Antileishmanial Agent-17 is a coumarin hybrid compound that targets the folate pathway enzymes pteridine reductase and dihydrofolate reductase-thymidylate synthase (DHFR-TS). It exhibits significant antileishmanial activity, demonstrating an IC50 of less than 0.78 μM, with a maximum potency of 0.40 μM against promastigotes and 0.68 μM against amastigotes. Moreover, it is non-toxic to normal VERO cells, making it a promising candidate for research in leishmaniasis treatment. -
Parasite Inhibitor
MMV666810 is a potent parasite inhibitor that targets asexual stages of parasites, exhibiting an IC50 of 5.94 nM. Notably, it demonstrates a 3.3-fold selectivity for late-stage gametocytes over earlier stages, with IC50 values of 179 ± 8 nM for late-stage and 603 ± 88 nM for early-stage gametocytes. This compound is valuable for research applications focused on antimalarial drug development and understanding gametocyte biology. -
Antileishmanial Agent
Antileishmanial agent-13 is a quinoline-isatin hybrid that functions as an effective antileishmanial agent targeting the L. major strain of Leishmania. This compound exerts its activity through an anti-folate mechanism, demonstrating potent inhibition against both promastigote and amastigote forms, with IC50 values of 0.604 μM and 0.508 μM, respectively. Its significant biological activity makes it a valuable reagent for research in Leishmaniasis treatment and drug development. -
Antileishmanial Agent
Sitamaquine tosylate is an 8-aminoquinoline analog that functions as an antileishmanial agent by inhibiting mitochondrial complex II (succinate dehydrogenase). This compound exhibits significant biological activity through its ability to rapidly accumulate in the acidic compartments of Leishmania species, particularly in acidocalcisomes, due to its lipophilic weak base characteristics. Sitamaquine tosylate is utilized in research aimed at understanding and combating leishmaniasis. -
Parasite Inhibitor
3-ANOT is a metabolite of Dinitolmide, functioning primarily as a parasite inhibitor. It demonstrates significant efficacy against coccidia, making it essential for research into antiparasitic mechanisms. 3-ANOT is applicable in studies focused on the prevention and treatment of parasitic infections in livestock, especially in poultry. -
Parasite Inhibitor
IWY357 is a potent inhibitor of Plasmodium falciparum, specifically targeting the blood stage of the parasite. This compound exhibits significant efficacy in disrupting the life cycle of the parasite, making it a valuable tool for researchers investigating malaria infection mechanisms and developing therapeutic strategies. Its long-acting properties can contribute to the understanding of parasite biology and assist in the design of novel anti-malarial drugs. -
Antileishmanial Agent
Antileishmanial agent-12 is a potent anti-leishmanial agent targeting protozoan parasites. It exhibits significant antiprotozoal activity against Leishmania braziliensis and Leishmania infantum, showing IC50 values of 14.9 μM and 21.3 μM respectively, as well as against T. cruzi with an IC50 value of 9.3 μM. This compound is applicable in research focused on the treatment of leishmaniasis and Chagas disease, contributing to the development of new therapeutic strategies against these infections. -
Parasite Inhibitor
Nopol is a quinoline derivative that acts as a potent inhibitor of the asexual blood stage of Plasmodium falciparum. Its structural variations result in differing biological activities against various Plasmodium strains, with certain derivatives exhibiting submicromolar EC50 values for specific strains. This compound is valuable for research focused on malaria treatment and the development of antimalarial agents. -
Antileishmanial Agent
Antileishmanial agent-8 is a targeted antileishmanial agent that exhibits potent activity against Leishmania donovani with an IC50 value of 5.64 μM. This compound demonstrates a favorable safety profile, exhibiting relatively low cytotoxicity in L-6 cells with an IC50 of 73.9 μM. Antileishmanial agent-8 is ideal for research applications focused on developing treatments for leishmaniasis.
